Therapeutic Romiplostim fusion protein from the original Nplate® commercial drug.
Product Batch | Therapeutic Expiry Date | Brand & Origin | Amount per Aliquot | Select Quantity | Discount | Price per Aliquot | |
|---|---|---|---|---|---|---|---|
2025.05 |
Nplate® DE |
0.02 mg |
Max: 4
Min: 1
Step: 1
|
631,00 €
/aliquot
|
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Here you will find the product information for the reference product.
| Drug name | Nplate® |
| INN | Romiplostim |
| API type | Fc-peptide fusion protein (peptibody) |
| Pharmacotherapeutic group | Antihaemorrhagics, other systemic haemostatics |
| ATC code | B02BX04 |
| Target of antibody | TPO receptor (also known as cMpl) |
| General function | Romoplostim is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Romiplostim is an Fc-peptide fusion protein (peptibody) that signals and activates intracellular transcriptional pathways via the TPO receptor (also known as cMpl) to increase platelet production. The peptibody molecule is comprised of a human immunoglobulin IgG1 Fc domain, with each single-chain subunit covalently linked at the C-terminus to a peptide chain containing 2 TPO receptor-binding domains. Romiplostim has no amino acid sequence homology to endogenous TPO. In pre-clinical and clinical trials no anti-romiplostim antibodies cross reacted with endogenous TPO. The pharmacokinetics of romiplostim involved target-mediated disposition, which is presumably mediated by TPO receptors on platelets and other cells of the thrombopoietic lineage such as megakaryocytes. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | The pharmacokinetics of romiplostim involved target-mediated disposition, which is presumably mediated by TPO receptors on platelets and other cells of the thrombopoietic lineage such as megakaryocytes. Due to the formation of neutralising antibodies pharmacodynamic effects of romiplostim in rats were often decreasing at prolonged duration of administration. Toxicokinetic studies showed no interaction of the antibodies with the measured concentrations. |
| Original license holder | Amgen Europe B.V. |
| Marketing authorisation numbers | EU/1/08/497/001 |
| Marketing authorisation holder | Amgen Europe B.V. Minervum 7061 4817 ZK Breda The Netherlands |
| Name of the manufacturer of the biological active substance | Amgen Inc One Amgen Center Drive Thousand Oaks, CA 91320 USA |
| Name and address of the manufacturer(s) responsible for batch release | Amgen Europe B.V. Minervum 7061 NL-4817 ZK Breda The Netherlands |
| Max shelf life | 3 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | Mannitol (E421), Sucrose, L-histidine, Hydrochloric acid (for pH adjustment), Polysorbate 20 |
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Receive a confidential, non-binding quote for the molecule(s) you choose.
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.